Figure 4

Assessment of maturation in NK cell subsets of healthy and HIV-1-infected subjects. A, Frequency of CD7⁺CD56⁺CD16⁺ and CD7⁺CD56^negCD16⁺ NK cells expressing CD57 in healthy (n = 62) and early (n = 9) and chronically (n = 19) HIV-1-infected subjects. B, The MFI of CD16 expression was assessed on CD7⁺CD56⁺CD16⁺ and CD7⁺CD56^negCD16⁺ NK cells in healthy (n = 52) and early (n = 9) HIV-1-infected subjects (left half), and in healthy (n = 10) and chronically HIV-1-infected subjects (n = 19) (right half). The healthy controls and early HIV-1 subjects were stained and analyzed in a different study with an anti-CD16 antibody conjugated to a different fluorophore than the healthy controls and chronic HIV-1-infected subjects. Therefore, early and chronic HIV-1-infected subjects cannot be directly compared with regard to mean fluorescent intensity. C, The frequency of CD7⁺CD56⁺CD16⁺ and CD7⁺CD56^negCD16⁺ NK cells expressing Siglec-7. D-E, The frequency of CD7⁺CD56^brightCD16^neg, CD7⁺CD56⁺CD16⁺ and CD7⁺CD56^negCD16⁺ NK cells expressing D) CD62L and E) CXCR3. The same healthy (n = 10) and chronic HIV-1-infected subjects (n = 19) used in 4B were used to assess Siglec-7, CD62L and CXCR3. The median and 25th and 75th percentile are indicated on each graph. ( = healthy; = HIV-1-infected).